Aclaris Therapeutics (ACRS) Operating Income (2014 - 2026)

Aclaris Therapeutics' Operating Income history runs 13 years deep, the most recent figure standing at -$22.2 million for Q1 2026.

• In Q1 2026, Operating Income fell 22.72% year-over-year to -$22.2 million; the TTM figure through Mar 2026 stood at -$80.5 million (up 42.95% YoY), while the FY2025 annual figure was -$76.4 million, up 46.19% from the prior year.
• Operating Income for Q1 2026 stood at -$22.2 million, up from -$22.7 million in the prior quarter.
• The five-year high for Operating Income was -$4.0 million in Q4 2023, with the low at -$99.7 million in Q4 2024.
• The 5-year median for Operating Income is -$20.9 million (2022), against an average of -$25.2 million.
• The sharpest annual moves came in 2023 and 2024: Operating Income surged 86.08% in 2023, then plunged 2362.94% in 2024.
• Aclaris Therapeutics' Operating Income stood at -$29.1 million in 2022, then soared by 86.08% to -$4.0 million in 2023, then slumped by 2362.94% to -$99.7 million in 2024, then surged by 77.19% to -$22.7 million in 2025, then advanced by 2.38% to -$22.2 million in 2026.
• Business Quant data shows ACRS's Operating Income at -$22.2 million in Q1 2026, -$22.7 million in Q4 2025, and -$17.1 million in Q3 2025.